A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
Public ClinicalTrials.gov record NCT02307513. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease
Study identification
- NCT ID
- NCT02307513
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 207 participants
Conditions and interventions
Conditions
Interventions
- Apremilast Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2014
- Primary completion
- Sep 24, 2017
- Completion
- Jul 16, 2020
- Last update posted
- Jul 21, 2021
2014 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Arthritis and Rheumatology Research, PLLC | Phoenix | Arizona | 85032 | — |
| University of California Davis Medical Center | Sacramento | California | 95816 | — |
| Millennium Research | Ormond Beach | Florida | 32174 | — |
| Arthritis and Rheumatology of Georgia | Atlanta | Georgia | 30342 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Advanced Rheumatology | Lansing | Michigan | 48910 | — |
| Shores Rheumatology | Saint Clair Shores | Michigan | 48081 | — |
| University of New Mexico | Albuquerque | New Mexico | 87131 | — |
| New York Methodist Hospital | Brooklyn | New York | 11215 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| University of Pennsylvania Health Systems | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02307513, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02307513 live on ClinicalTrials.gov.